Home › NDC Lookup › Ingredients › Potassium Chloride › 00245-5317-11
KLOR-CON M potassium chloride 750 mg Tablet, Extended Release, 100-count — NDC 00245-5317-11 package photo

KLOR-CON M potassium chloride 750 mg Tablet, Extended Release, 100-count

by Upsher-Smith Laboratories, LLC · 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (0245-5317-11)
NDC 00245-5317-11
🏷️ FDA NDC (as labeled) 0245-5317-11 billing pads the labeler segment with a zero
This package
Contains100-count Cost per ea$0.1566 NADAC Per package$15.66 / 100 tablets Pack sizes4 compare ↓
Also priced by: Medicaid pays $0.2695/unit · Part D plans $0.2440/unit — full pricing hub ↓
Also comes in: 1 tablet 00245-5317-01 90 tablets 00245-5317-90 1000 tablets 00245-5317-10
Rx only Generic On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Potassium Chloride (different manufacturers) — 6 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class I · Oct 29, 2025 — Labeling: Label Error on Declared Strength-The overwrap label may incorrectly identify the product as POTASSIUM CHLORIDE Inj. 10 mEq instead of POTASSIUM CHLORIDE Inj. 20 mEq (Otsuka ICU Medical LLC) · FDA recall D-0181-2026
Class I · Oct 29, 2025 — Labeling: Label Error on Declared Strength-The overwrap label may incorrectly identify the product as POTASSIUM CHLORIDE Inj. 10 mEq instead of POTASSIUM CHLORIDE Inj. 20 mEq (Otsuka ICU Medical LLC) · FDA recall D-0180-2026
Class I · Feb 13, 2025 — Labeling: Label Error on Declared Strength. Overwrap labeled as Potassium Chloride Inj 10 mEq may contain flexible containers of Potassium Chloride Inj 20 mEq (ICU Medical, Inc.) · FDA recall D-0268-2025
Class I · Feb 13, 2025 — Labeling: Label Error on Declared Strength. Cases labeled POTASSIUM CHLORIDE 20 mEq, may contain flexible containers with overwrap mislabeled as 10 mEq. The correct dosage strength of 20 mEq is printed on the labeling affixed to the product flexible container. (ICU Medical, Inc.) · FDA recall D-0267-2025
Class II · Jan 30, 2025 — Failed Dissolution Specifications. (The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories) · FDA recall D-0221-2025
Class I · Jun 25, 2024 — Failed Dissolution Specifications (Amerisource Health Services LLC) · FDA recall D-0619-2024
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

🆔 Identity & classification

FDA NDC (as labeled) 0245-5317-11
Product NDC 0245-5317
11-digit billing NDC 00245531711
NCPDP billing unit EA — each (per item)
RxCUI 403888, 832731, 1801294, 1801295, 1801298, 1801299
UNII 660YQ98I10
Application # ANDA074726
SPL Set ID b89910f6-4ff5-4a62-8269-696f7c10e4f6
Established class (EPC) Osmotic Laxative; Potassium Salt
Mechanism of action Osmotic Activity
Physiologic effect Increased Large Intestinal Motility; Inhibition Large Intestine Fluid/Electrolyte Absorption
Chemical class Potassium Compounds
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2011-01-18
Route ORAL
Dosage form TABLET, EXTENDED RELEASE
Substance POTASSIUM CHLORIDE
GPI-14 79700030100430
GPI class Klor-Con M10
GCN Seq No 022345
GCN 03512
HICL code 000549
Ingredient (HICL) Potassium Chloride
HIC1 code C
Therapeutic class — broad (HIC1) Electrolyte Balance/Metabolism/Nutrition
HIC2 code C1
Therapeutic class — intermediate (HIC2) Drugs Affecting Electrolyte Balance
HIC3 code C1D
Therapeutic class — specific (HIC3) Potassium Replacement
AHFS code 40:12.00.00
AHFS class Replacement Preparations
FDB label name KLOR-CON M10 TABLET
FDB brand name Klor-Con M10
Legend status F — Federal legend — prescription drug or device
TE code (Orange Book) AB1 · RLD · RS
Why two NDCs? The FDA registers this code as 0245-5317-11 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00245-5317-11. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Potassium class.

Drug family (ATC) Potassium, Electrolyte solutions
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerUpsher-Smith Laboratories, LLC
Application holderUPSHER SMITH LABORATORIES LLC
FDA applicationANDA074726 (ANDA)
Labeler code00245
First marketedJan 2011
Product typeHuman Prescription Drug
Portfolio228 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name KLOR-CON M10 TABLET Ingredient Potassium Chloride
📗 Our plain-language guide HelloPharmacist
  • You're right that food is the first line — bananas, potatoes, and leafy greens are all rich in potassium. But sometimes diet alone isn't enough, especially if you're taking a diure...
  • Why did my doctor prescribe potassium chloride? I thought potassium just came from bananas.
  • Yes — always take oral tablets or capsules with a meal or right after eating. Taking them on an empty stomach can irritate or even ulcerate the lining of your stomach or intestines...
  • Do I have to take it with food? What happens if I forget?
📖 Read our full Potassium Chloride guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

💊 What it looks like

Color white
ShapeOval
ImprintKC;M20
Size22 mm
ScoringScored — splits in 2
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII M28OL1HH48
    Croscarmellose sodium is a plant-based substance derived from cellulose. It acts as a disintegrant, helping tablets and capsules break down quickly in the digestive system so the medicine can be absorbed.
  • UNII 7Z8S9VYZ4B
    Ethylcellulose is a plant-derived thickener and film-former made by chemically modifying cellulose. It's used as a binder to hold tablet ingredients together, a coating to control how quickly medicine is released, or a thickener in liquid formulations.
  • UNII OP1R32D61U
    Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.

3 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.157 $15.66 / 100 tablets
Medicaid paysCMS SDUD · 12 mo $0.2695 $26.95 / 100 tablets
Medicare drug plans payPart D · Q2 2026 $0.2440 $24.40 / 100 tablets
NADAC price history (per ea) — tap or hover for the price & month
May 2022 Feb 2026 May 2026 Aug 2026 $0.201 $0.116
▼ Down 22% over the last 9 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Potassium Chloride 750 mg 65862-0987-01 Aurobindo 100 tablets $0.084 AB2 Availability likely save 47%
Potassium Chloride 750 mg 68001-0518-00 BluePoint 100 tablets $0.084 AB2 Availability likely save 47%
Potassium Chloride Extended Release 750 mg 70010-0022-01 Granules 100 tablets $0.084 AB2 Availability likely save 47%
Potassium Chloride Extended Release 750 mg 16571-0843-01 Rising 100 tablets $0.084 AB2 Availability likely save 47%
Potassium Chloride Extended-Release 750 mg 24979-0231-01 Upsher-Smith 100 tablets $0.084 AB3 Availability likely save 47%
Potassium Chloride 750 mg 00832-5323-10 Upsher-Smith 1000 tablets $0.084 AB2 Availability likely save 47%
Potassium Chloride 750 mg 64380-0861-06 Strides 100 tablets $0.084 AB2 Availability likely save 47%
Potassium Chloride 750 mg 00904-7216-61 Major 1 tablet $0.084 AB2 Availability likely save 47%
Potassium Chloride 750 mg 60687-0810-09 American 1 tablet $0.084 AB2 Availability likely save 47%
Potassium Chloride 750 mg 42806-0423-01 Epic 100 tablets $0.084 AB2 Availability likely save 47%
Potassium chloride 750 mg 72888-0075-00 Advagen 1000 tablets $0.084 — Availability likely save 47%
Potassium Chloride 750 mg 70436-0002-01 Slate 100 tablets $0.110 AB2 FDA listed save 30%
Klor-Con 750 mg 00245-0836-11 Upsher-Smith 100 tablets $0.123 AB2 Availability likely save 21%
Klor-Con 750 mg 00245-5316-01 Upsher-Smith 1 tablet $0.123 AB2 Availability likely save 21%
Potassium Chloride 750 mg 00832-5324-10 Upsher-SmithLaboratories, 1000 tablets $0.130 AB1 Availability likely save 17%
Potassium Chloride Extended-Release 750 mg 00904-7547-61 Major 1 tablet $0.130 AB1 Availability likely save 17%
Potassium Chloride 750 mg 31722-0133-01 Camber 100 tablets $0.130 AB1 Availability likely save 17%
Potassium Chloride Extended-Release 750 mg 60687-0632-01 American 1 tablet $0.130 AB1 Availability likely save 17%
Potassium Chloride Extended-Release 750 mg 63304-0076-01 Sun 100 tablets $0.130 AB1 Availability likely save 17%
Potassium Chloride Extended-release 750 mg 68001-0566-00 Bluepoint 100 tablets $0.130 AB1 Availability likely save 17%
potassium chloride 750 mg 68462-0471-01 Glenmark 100 tablets $0.130 AB1 Discontinued save 17%
Potassium Chloride Extended-release 750 mg 70010-0136-01 Granules 100 tablets $0.130 AB1 Availability likely save 17%
potassium chloride 750 mg 72603-0337-01 Northstar 100 tablets $0.130 AB1 Availability likely save 17%
Potassium Chloride 750 mg 00904-7292-61 Major 1 tablet $0.135 — Discontinued save 14%
Potassium Chloride 10 meq 62037-0710-01 Actavis 100 tablets $0.135 AB1 Discontinued save 14%
Potassium Chloride 10 meq 43386-0915-01 Lupin 100 tablets $0.150 AB1 FDA listed save 5%
Potassium Chloride 750 mg 63739-0972-10 Mckesson 10 tablets $0.150 AB1 Discontinued save 5%
Klor-Con M 750 mgthis 00245-5317-11 Upsher-Smith 100 tablets $0.157 AB1 Availability likely —
Potassium Chloride Extended-Release 750 mg 00615-8399-05 NCS 15 tablets — AB1 FDA listed —
Potassium Chloride 750 mg 43547-0549-10 Solco 100 tablets — AB1 FDA listed —
Potassium Chloride 750 mg 59651-0429-01 Aurobindo 100 tablets — — FDA listed —
Potassium Chloride Extended-release 750 mg 62207-0726-43 Granules 100 tablets — AB1 FDA listed —
Potassium Chloride Extended-Release 750 mg 63629-1072-01 Bryant 100 tablets — AB1 FDA listed —
Potassium Chloride Extended-Release 750 mg 63629-1073-01 Bryant 1000 tablets — AB1 FDA listed —
Potassium Chloride Extended-Release 750 mg 63629-1074-01 Bryant 90 tablets — AB1 FDA listed —
Potassium Chloride Extended-Release 750 mg 63629-1075-01 Bryant 500 tablets — AB1 FDA listed —
Potassium Chloride 750 mg 68382-0861-01 Zydus 100 tablets — AB1 FDA listed —
Potassium Chloride Extended-Release 750 mg 70518-3024-01 REMEDYREPACK 90 tablets — AB1 FDA listed —
Potassium Chloride Extended-release 750 mg 70518-4095-02 REMEDYREPACK 30 tablets — AB1 FDA listed —
Potassium Chloride 750 mg 70771-1599-00 Zydus 1000 tablets — AB1 FDA listed —
potassium chloride 750 mg 71335-1781-01 Bryant 30 tablets — AB1 Discontinued —
Potassium Chloride Extended-Release 750 mg 71335-1900-01 Bryant 30 tablets — AB1 FDA listed —
Potassium Chloride Extended-release 750 mg 71335-2503-01 Bryant 30 tablets — AB1 FDA listed —
Potassium Chloride Extended-Release 750 mg 71335-2607-01 Bryant 30 tablets — AB1 FDA listed —
Potassium Chloride Extended-Release 750 mg 71335-2866-01 Bryant 100 tablets — AB1 FDA listed —
Potassium Chloride Extended-Release 750 mg 71335-2913-01 Bryant 500 tablets — AB1 FDA listed —
Potassium Chloride Extended-Release 750 mg 71335-2958-01 Bryant 90 tablets — AB1 FDA listed —
Potassium Chloride Extended-Release 750 mg 72162-1786-00 Bryant 1000 tablets — AB1 FDA listed —
Potassium Chloride ER 750 mg 72189-0648-04 Direct_Rx 4 tablets — AB1 FDA listed —
Potassium Chloride 750 mg 72865-0194-01 XLCare 100 tablets — AB1 FDA listed —
Potassium Chloride 750 mg 72888-0097-00 Advagen 1000 tablets — AB1 FDA listed —
Potassium Chloride Extended-release 750 mg 82804-0109-30 Proficient 30 tablets — AB1 FDA listed —
Potassium Chloride 750 mg 82868-0027-90 Northwind 90 tablets — AB1 FDA listed —
Potassium Chloride 750 mg 50090-5335-00 A-S 30 tablets — AB2 FDA listed —
Potassium Chloride Extended-Release 750 mg 50090-6640-00 A-S 90 tablets — AB3 FDA listed —
Potassium chloride extended release 750 mg 63629-8442-01 Bryant 100 tablets — AB2 Discontinued —
Potassium Chloride Extended-Release 750 mg 50090-6639-00 A-S 30 tablets — AB3 FDA listed —
Potassium Chloride 750 mg 50090-7378-00 A-S 30 tablets — AB2 FDA listed —
Potassium chloride 750 mg 50090-7748-00 A-S 30 tablets — — FDA listed —
Potassium Chloride 750 mg 71335-1131-01 Bryant 30 tablets — AB2 FDA listed —
Potassium Chloride 750 mg 50090-7639-00 A-S 30 tablets — AB2 FDA listed —
Potassium Chloride 750 mg 68788-8262-03 Preferred 30 tablets — AB2 FDA listed —
Potassium Chloride Extended-Release 750 mg 71335-2447-01 Bryant 30 tablets — AB3 FDA listed —
Potassium Chloride 750 mg 71610-0349-15 Aphena 15 tablets — AB2 FDA listed —
Potassium Chloride 750 mg 71610-0977-30 Aphena 30 tablets — AB2 FDA listed —
Potassium Chloride 750 mg 24979-0230-00 Upsher-Smith 64000 tablets — AB2 FDA listed —
Potassium Chloride 750 mg 42291-0506-01 AvKARE 100 tablets — AB2 FDA listed —
Potassium Chloride Extended Release 750 mg 70518-4520-00 REMEDYREPACK 30 tablets — AB2 FDA listed —
Potassium Chloride Extended-Release 750 mg 71610-0935-60 Aphena 90 tablets — AB3 FDA listed —
Potassium chloride 750 mg 72789-0503-95 PD-Rx 1000 tablets — — FDA listed —
Potassium Chloride 750 mg 00615-8570-05 NCS 15 tablets — AB2 FDA listed —
Potassium Chloride 750 mg 42291-0487-01 AvKARE 100 tablets — AB2 FDA listed —
Potassium chloride 750 mg 33342-0418-11 Macleods 100 tablets — AB2 FDA listed —
Potassium Chloride 750 mg 50090-7379-00 A-S 90 tablets — AB2 FDA listed —
Potassium Chloride 750 mg 70518-2964-00 REMEDYREPACK 30 tablets — AB2 FDA listed —
Potassium Chloride 750 mg 50090-7640-00 A-S 90 tablets — AB2 FDA listed —
Potassium Chloride 750 mg 51655-0226-26 Northwind 90 tablets — AB2 FDA listed —
Potassium Chloride Extended Release 750 mg 71610-0932-60 Aphena 90 tablets — AB2 FDA listed —
Potassium Chloride 750 mg 51655-0706-52 Northwind 30 tablets — AB2 FDA listed —
Potassium Chloride 750 mg 71610-0944-30 Aphena 30 tablets — AB2 FDA listed —
Potassium chloride 750 mg 71610-0960-60 Aphena 90 tablets — — FDA listed —
Potassium Chloride 750 mg 82804-0187-30 Proficient 30 tablets — AB2 FDA listed —
Potassium chloride 750 mg 50090-7749-00 A-S 90 tablets — — FDA listed —
Potassium Chloride 750 mg 51655-0463-84 Northwind 14 tablets — AB2 FDA listed —
Potassium Chloride 750 mg 60760-0423-90 St. 90 tablets — AB2 FDA listed —
Potassium Chloride 750 mg 71610-0945-30 Aphena 30 tablets — AB2 FDA listed —
Potassium Chloride 750 mg 72189-0027-04 Direct_Rx 4 tablets — AB2 FDA listed —
Potassium Chloride 750 mg 70436-0152-01 Slate 100 tablets — AB3 FDA listed —
Potassium Chloride 750 mg 82868-0111-90 Northwind 90 tablets — AB2 FDA listed —
Potassium Chloride 750 mg 67046-1032-03 Coupler 30 tablets — AB2 FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️
2011
On the market since
Jan 2011
📍
2026
Currently FDA-listed
15 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 00245-5317-11, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
4.1K
Units reimbursed last 4 qtrs
216.4K
Gross reimbursed last 4 qtrs
$58.3K
Avg / prescription
$14.15
Avg / unit
$0.2695
Latest quarter Q4 2025
924Rx
Medicaid pays / ea
$0.2695
gross reimbursed
vs
NADAC / ea
$0.1566
acquisition cost
=
Spread
+$0.1129
+72% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
32% FFS 68% MCO
Fee-for-service · 1,326 Rx Managed care · 2,797 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: 5,398 units · 689 per 100k residents ND Minnesota: 20,163 units · 351 per 100k residents MN Wisconsin: 1,198 units · 20.3 per 100k residents WI Michigan: 6,688 units · 66.6 per 100k residents MI New York: 61,001 units · 312 per 100k residents NY Vermont: 1,290 units · 199 per 100k residents VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 4,386 units · 137 per 100k residents IA Illinois: 8,695 units · 69.3 per 100k residents IL Indiana: 9,625 units · 140 per 100k residents IN Ohio: 12,332 units · 105 per 100k residents OH Pennsylvania: 14,278 units · 110 per 100k residents PA New Jersey: 4,261 units · 45.9 per 100k residents NJ Massachusetts: 14,058 units · 201 per 100k residents MA California: no data reported CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: 3,076 units · 49.6 per 100k residents MO Kentucky: 3,601 units · 79.6 per 100k residents KY West Virginia: 4,456 units · 252 per 100k residents WV Virginia: 17,057 units · 196 per 100k residents VA Maryland: 6,625 units · 107 per 100k residents MD Connecticut: no data reported CT Rhode Island: 682 units · 62.3 per 100k residents RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: 510 units · 17.3 per 100k residents KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: 10,635 units · 98.2 per 100k residents NC South Carolina: 2,031 units · 37.8 per 100k residents SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: 3,247 units · 29.4 per 100k residents GA D.C.: 1,145 units · 169 per 100k residents DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
17.3689
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 North Dakota 689 /100k
2 Minnesota 351 /100k
3 New York 312 /100k
4 West Virginia 252 /100k
5 Massachusetts 201 /100k
6 Vermont 199 /100k
7 Virginia 196 /100k
8 D.C. 169 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

💊 Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
100 tablets this page00245-5317-11 4,123 Rx · $58,334
1 tablet00245-5317-01 622 Rx · $3,192
1000 tablets00245-5317-10 280 Rx · $34,559
90 tablets00245-5317-90 168 Rx · $1,856
Drug total (last 4 qtrs): 5,193 Rx · 241,948 units · $97,941 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Potassium Chloride (matched by generic name) — the program that covers self-administered drugs. 42 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Potassium Chloride. CMS lists 8 products for this generic; we show the highest-spend one. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$78.71M
Claims incl. refills
3.7M
Beneficiaries
2.4M
Spend / beneficiary
$33.46
Spend / claim
$21.47
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

📦 Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startStatus
00245-5317-01 100 BLISTER PACK in 1 CARTON (0245-5317-01) / 1 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (0245-5317-89) $0.1566 / ea $15.66 2019-06-21 Active
00245-5317-10 1000 TABLET, EXTENDED RELEASE in 1 BOTTLE (0245-5317-10) $0.1566 / ea $156.56 2019-06-21 Active
00245-5317-11 You're viewing this 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (0245-5317-11) $0.1566 / ea $15.66 2019-06-21 Active
00245-5317-90 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (0245-5317-90) $0.1566 / ea $14.09 2019-06-21 Active

This pack effectively ties for the lowest per-ea cost of the 4 priced pack sizes ($0.1566 NADAC).

In Medicaid, this is the most-dispensed pack of this product — about 79% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in NDC 00245-5317-11?
NDC 00245-5317-11 is a 100-count package — 100 tablet, extended release in 1 bottle.
What is the difference between NDC 00245-5317-11 and NDC 00245-5317-90?
Both are KLOR-CON M potassium chloride 750 mg Tablet, Extended Release — the drug itself is identical. NDC 00245-5317-11 is the 100-count package, while NDC 00245-5317-90 is the 90 tablets package.
What NDC number is used to bill for this package of KLOR-CON M potassium chloride 750 mg Tablet, Extended Release?
Bill NDC 00245-5317-11 — the 11-digit billing format is 00245531711. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🔄 Drug Interactions 🤰 Pregnancy 🧒 Pediatric Use 🧓 Geriatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description 💬 Information for Patients
🎯 Indications and Usage 209 words ▾

INDICATIONS AND USAGE BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication and in patients with hypokalemic familial periodic paralysis.

If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used.

Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated.

⏱️ Dosage and Administration ~2 min read ▾

DOSAGE AND ADMINISTRATION The usual dietary intake of potassium by the average adult is 50 to 100 mEq per day. Potassium depletion sufficient to cause hypokalemia usually requires the loss of 200 or more mEq of potassium from the total body store. Dosage must be adjusted to the individual needs of each patient.

The dose for the prevention of hypokalemia is typically in the range of 20 mEq per day. Doses of 40 to 100 mEq per day or more are used for the treatment of potassium depletion. Dosage should be divided if more than 20 mEq per day is given such that no more than 20 mEq is given in a single dose.

Each Klor-Con ® M10 tablet provides 750 mg of potassium chloride equivalent to 10 mEq of potassium. Each Klor-Con ® M15 tablet provides 1125 mg of potassium chloride equivalent to 15 mEq of potassium. Each Klor-Con ® M20 tablet provides 1500 mg of potassium chloride equivalent to 20 mEq of potassium.

Klor-Con M tablets should be taken with meals and with a glass of water or other liquid. This product should not be taken on an empty stomach because of its potential for gastric irritation [see WARNINGS ]. Patients having difficulty swallowing whole tablets may try one of the following alternate methods of administration: Break the tablet in half and take each half separately with a glass of water.

Prepare an aqueous (water) suspension as follows: Place the whole tablet(s) in approximately ½ glass of water (4 fluid ounces). Allow approximately 2 minutes for the tablet(s) to disintegrate. Stir for about half a minute after the tablet(s) has disintegrated.

Swirl the suspension and consume the entire contents of the glass immediately by drinking or by the use of a straw. Add another 1 fluid ounce of water, swirl, and consume immediately. Then, add an additional 1 fluid ounce of water, swirl, and consume immediately.

Aqueous suspension of potassium chloride that is not taken immediately should be discarded. The use of other liquids for suspending potassium chloride is not recommended.

⛔ Contraindications 174 words ▾

CONTRAINDICATIONS Potassium supplements are contraindicated in patients with hyperkalemia since a further increase in serum potassium concentration in such patients can produce cardiac arrest. Hyperkalemia may complicate any of the following conditions: chronic renal failure, systemic acidosis, such as diabetic acidosis, acute dehydration, extensive tissue breakdown as in severe burns, adrenal insufficiency, or the administration of a potassium-sparing diuretic (e.g., spironolactone, triamterene, or amiloride) [see OVERDOSAGE ].

Controlled-release formulations of potassium chloride have produced esophageal ulceration in certain cardiac patients with esophageal compression due to enlarged left atrium. Potassium supplementation, when indicated in such patients, should be given as a liquid preparation or as an aqueous (water) suspension of potassium chloride [see PRECAUTIONS: Information for Patients and DOSAGE AND ADMINISTRATION ]. All solid oral dosage forms of potassium chloride are contraindicated in any patient in whom there is structural, pathological (e.g., diabetic gastroparesis), or pharmacologic (use of anticholinergic agents or other agents with anticholinergic properties at sufficient doses to exert anticholinergic effects) cause for arrest or delay in tablet passage through the gastrointestinal tract.

⚠️ Warnings ~2 min read ▾

WARNINGS Hyperkalemia [see OVERDOSAGE ] In patients with impaired mechanisms for excreting potassium, the administration of potassium salts can produce hyperkalemia and cardiac arrest. This occurs most commonly in patients given potassium by the intravenous route but may also occur in patients given potassium orally. Potentially fatal hyperkalemia can develop rapidly and be asymptomatic.

The use of potassium salts in patients with chronic renal disease, or any other condition which impairs potassium excretion, requires particularly careful monitoring of the serum potassium concentration and appropriate dosage adjustment. Interaction with Potassium-Sparing Diuretics Hypokalemia should not be treated by the concomitant administration of potassium salts and a potassium-sparing diuretic (e.g., spironolactone, triamterene, or amiloride) since the simultaneous administration of these agents can produce severe hyperkalemia.

Interaction with Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. Interaction with Nonsteroidal Anti-Inflammatory Drugs Nonsteroidal anti-inflammatory drugs (NSAIDs) may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.

Closely monitor potassium in patients receiving concomitant NSAID therapy. Gastrointestinal Lesions Solid oral dosage forms of potassium chloride can produce ulcerative and/or stenotic lesions of the gastrointestinal tract. Based on spontaneous adverse reaction reports, enteric-coated preparations of potassium chloride are associated with an increased frequency of small bowel lesions (40 to 50 per 100,000 patient years) compared to sustained-release wax matrix formulations (less than one per 100,000 patient years).

Because of the lack of extensive marketing experience with microencapsulated products, a comparison between such products and wax matrix or enteric-coated products is not available. Klor-Con M is a tablet formulated to provide an controlled rate of release of microencapsulated potassium chloride and thus to minimize the possibility of a high local concentration of potassium near the gastrointestinal wall. Prospective trials have been conducted in normal human volunteers in which the upper gastrointestinal tract was evaluated by endoscopic inspection before and after 1 week of solid oral potassium chloride therapy.

The ability of this model to predict events occurring in usual clinical practice is unknown. Trials which approximated usual clinical practice did not reveal any clear differences between the wax matrix and microencapsulated dosage forms. In contrast, there was a higher incidence of gastric and duodenal lesions in subjects receiving a high dose of a wax matrix controlled-release formulation under conditions which did not resemble usual or recommended clinical practice (i.e., 96 mEq per day in divided doses of potassium chloride administered to fasted patients, in the presence of an anticholinergic drug to delay gastric emptying).

The upper gastrointestinal lesions observed by endoscopy were asymptomatic and were not accompanied by evidence of bleeding (Hemoccult testing). The relevance of these findings to the usual conditions (i.e., non-fasting, no anticholinergic agent, smaller doses) under which controlled-release potassium chloride products are used is uncertain; epidemiologic studies have not identified an elevated risk, compared to microencapsulated products, for upper gastrointestinal lesions in patients receiving wax matrix formulations.

Klor-Con M tablets should be discontinued immediately, and the possibility of ulceration, obstruction, or perforation should be co…

🤒 Adverse Reactions 89 words ▾

ADVERSE REACTIONS One of the most severe adverse effects is hyperkalemia [see CONTRAINDICATIONS , WARNINGS and OVERDOSAGE ]. There have also been reports of upper and lower gastrointestinal conditions including obstruction, bleeding, ulceration, and perforation [see CONTRAINDICATIONS and WARNINGS ]. The most common adverse reactions to oral potassium salts are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea.

These symptoms are due to irritation of the gastrointestinal tract and are best managed by diluting the preparation further, taking the dose with meals or reducing the amount taken at one time.

🔄 Drug Interactions 10 words ▾

Drug Interactions Potassium-sparing diuretics, angiotensin-converting enzyme inhibitors [see WARNINGS ].

🤰 Pregnancy 36 words ▾

Pregnancy Animal reproduction studies have not been conducted with potassium chloride. It is unlikely that potassium supplementation that does not lead to hyperkalemia would have an adverse effect on the fetus or would affect reproductive capacity.

🧒 Pediatric Use 12 words ▾

Pediatric Use Safety and effectiveness in pediatric patients have not been established.

🧓 Geriatric Use 139 words ▾

Geriatric Use Clinical studies of potassium chloride did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection; and it may be useful to monitor renal function.

🆘 Overdosage ~1 min read ▾

OVERDOSAGE The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired or if potassium is administered too rapidly intravenously, potentially fatal hyperkalemia can result [see CONTRAINDICATIONS and WARNINGS ]. It is important to recognize that hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium concentration (6.5 to 8.0 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves, loss of P-waves, depression of S-T segment, and prolongation of the QT-interval).

Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L). Treatment measures for hyperkalemia include the following: Patients should be closely monitored for arrhythmias and electrolyte changes. Elimination of foods and medications containing potassium and of any agents with potassium-sparing properties such as potassium-sparing diuretics, ARBs, ACE inhibitors, NSAIDs, certain nutritional supplements and many others.

Intravenous calcium gluconate if the patient is at no risk or low risk of developing digitalis toxicity. Intravenous administration of 300 to 500 mL/hr of 10% dextrose solution containing 10 to 20 units of crystalline insulin per 1,000 mL. Correction of acidosis, if present, with intravenous sodium bicarbonate.

Use of exchange resins, hemodialysis, or peritoneal dialysis. In treating hyperkalemia, it should be recalled that in patients who have been stabilized on digitalis, too rapid a lowering of the serum potassium concentration can produce digitalis toxicity. The extended-release feature means that absorption and toxic effects may be delayed for hours.

Consider standard measures to remove any unabsorbed drug.

🧬 Clinical Pharmacology ~2 min read ▾

CLINICAL PHARMACOLOGY The potassium ion is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity; the transmission of nerve impulses; the contraction of cardiac, skeletal, and smooth muscle; and the maintenance of normal renal function. The intracellular concentration of potassium is approximately 150 to 160 mEq per liter.

The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane. Potassium is a normal dietary constituent and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine.

The usual dietary intake of potassium is 50 to 100 mEq per day. Potassium depletion will occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake. Such depletion usually develops as a consequence of therapy with diuretics, primary or secondary hyperaldosteronism, diabetic ketoacidosis or inadequate replacement of potassium in patients on prolonged parenteral nutrition.

Depletion can develop rapidly with severe diarrhea, especially if associated with vomiting. Potassium depletion due to these causes is usually accompanied by a concomitant loss of chloride and is manifested by hypokalemia and metabolic alkalosis. Potassium depletion may produce weakness, fatigue, disturbances or cardiac rhythm (primarily ectopic beats), prominent U-waves in the electrocardiogram, and in advanced cases, flaccid paralysis and/or impaired ability to concentrate urine.

If potassium depletion associated with metabolic alkalosis cannot be managed by correcting the fundamental cause of the deficiency, e.g., where the patient requires long-term diuretic therapy, supplemental potassium in the form of high-potassium food or potassium chloride may be able to restore normal potassium levels. In rare circumstances (e.g., patients with renal tubular acidosis) potassium depletion may be associated with metabolic acidosis and hyperchloremia. In such patients potassium replacement should be accomplished with potassium salts other than the chloride, such as potassium bicarbonate, potassium citrate, potassium acetate, or potassium gluconate.

📦 How Supplied / Storage and Handling 198 words ▾

HOW SUPPLIED Klor-Con ® M10 Extended-release Tablets, contains 750 mg of potassium chloride (equivalent to 10 mEq of potassium) are white, oblong tablets and imprinted "KC M10". They are supplied as follows: Bottles of 90 tablets NDC 0245-5317-90 Bottles of 100 tablets NDC 0245-5317-11 Bottles of 1,000 tablets NDC 0245-5317-10 Unit-dose cartons of 100 tablets NDC 0245-5317-01 Klor-Con ® M15 Extended-release Tablets, contains 1,125 mg of potassium chloride (equivalent to 15 mEq of potassium) are white, oblong tablets and imprinted "M 15" and scored for flexibility of dosing.

They are supplied as follows: Bottles of 100 tablets NDC 0245-5318-11 Unit-dose cartons of 100 tablets NDC 0245-5318-01 Klor-Con ® M20 Extended-release Tablets, contains 1,500 mg of potassium chloride (equivalent to 20 mEq of potassium) are white, oblong tablets and imprinted "KC M20" and scored for flexibility of dosing. They are supplied as follows: Bottles of 90 tablets NDC 0245-5319-90 Bottles of 100 tablets NDC 0245-5319-11 Bottles of 500 tablets NDC 0245-5319-15 Bottles of 1,000 tablets NDC 0245-5319-10 Unit-dose cartons of 100 tablets NDC 0245-5319-01 Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].

Keep tightly closed.

📦 Storage and Handling 25 words ▾

Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Keep tightly closed.

📋 Description ~1 min read ▾

DESCRIPTION Klor-Con ® M10 (potassium chloride extended-release tablets, USP) is an immediately dispersing extended-release oral dosage form of potassium chloride containing 750 mg of microencapsulated potassium chloride, USP equivalent to 10 mEq of potassium in a tablet. Klor-Con ® M15 (potassium chloride extended-release tablets, USP) is an immediately dispersing extended-release oral dosage form of potassium chloride containing 1,125 mg of microencapsulated potassium chloride, USP equivalent to 15 mEq of potassium in a tablet.

Klor-Con ® M20 (potassium chloride extended-release tablets, USP) is an immediately dispersing extended-release oral dosage form of potassium chloride containing 1,500 mg of microencapsulated potassium chloride, USP equivalent to 20 mEq of potassium in a tablet. These formulations are intended to slow the release of potassium so that the likelihood of a high localized concentration of potassium chloride within the gastrointestinal tract is reduced. Klor-Con ® M is an electrolyte replenisher.

The chemical name of the active ingredient is potassium chloride, and the structural formula is KCl. Potassium chloride, USP occurs as a white, granular powder or as colorless crystals. It is odorless and has a saline taste.

Its solutions are neutral to litmus. It is freely soluble in water and insoluble in alcohol. Klor-Con ® M is a tablet formulation (not enteric-coated or wax matrix) containing individually microencapsulated potassium chloride crystals which disperse upon tablet disintegration.

In simulated gastric fluid at 37°C and in the absence of outside agitation, Klor-Con ® M begins disintegrating into microencapsulated crystals within seconds and completely disintegrates within 1 minute. The microencapsulated crystals are formulated to provide an extended-release of potassium chloride, USP. Inactive Ingredients : croscarmellose sodium, ethylcellulose and microcrystalline cellulose.

💬 Information for Patients ~1 min read ▾

Information for Patients Physicians should consider reminding the patient of the following: To take each dose with meals and with a full glass of water or other liquid. To take each dose without crushing, chewing or sucking the tablets. If those patients are having difficulty swallowing whole tablets, they may try one of the following alternate methods of administration: Break the tablet in half and take each half separately with a glass of water.

Prepare an aqueous (water) suspension as follows: Place the whole tablet(s) in approximately ½ glass of water (4 fluid ounces). Allow approximately 2 minutes for the tablet(s) to disintegrate. Stir for about half a minute after the tablet(s) has disintegrated.

Swirl the suspension and consume the entire contents of the glass immediately by drinking or by the use of a straw. Add another 1 fluid ounce of water, swirl, and consume immediately. Then, add an additional 1 fluid ounce of water, swirl, and consume immediately.

Aqueous suspension of potassium chloride that is not taken immediately should be discarded. The use of other liquids for suspending potassium chloride tablets is not recommended. To take this medicine following the frequency and amount prescribed by the physician.

This is especially important if the patient is also taking diuretics and/or digitalis preparations. To check with the physician at once if tarry stools or other evidence of gastrointestinal bleeding is noticed.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
← 00245-5316-01 · Upsher-Smith 00245-5318-01 · Upsher-Smith →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.